By Christine Davis
Boca Raton Regional Hospital’s Marcus Neuroscience Institute has initiated a phase-two clinical trial of the immunotoxin MDNA55 in the treatment of patients with recurrent malignant brain tumors.
Highly toxic to brain tumor
